Swim beach closes at Aurora Reservoir due to elevated bacteria levels
Officials closed the swim beach at the Aurora Reservoir on Wednesday due to elevated levels of bacteria in the water.
The City of Aurora said the levels of bacteria naturally fluctuate in any untreated body of water, and it usually corrects itself. They advised that when bacteria levels are elevated, it's best not to swim there.
City of Aurora
The swim area is tested regularly, said the city. Officials said they will reopen the area as soon as the levels drop.
Kayaking, paddle boarding and the boating section of the reservoir are still open to the public.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Want to reduce your heart attack risk? Do this kind of exercise
When it comes to fortifying heart health and preventing a potential heart attack, cardiologists say one type of physical activity is better than the rest. Heart disease is the nation's top killer, with more than 371,000 Americans dying of coronary heart disease in 2022. 'Aerobic exercise training should be promoted above all else,' Dr. Luke Laffin, a preventive cardiologist and co-director of the Center for Blood Pressure Disorders at the Cleveland Clinic, told Aerobic exercises include walking or jogging, swimming or cycling – even dancing. These exercises raise your heart rate, with your cells using oxygen to produce energy, according to the Cleveland Clinic. They typically use large muscle groups in the body, too. Laffin says multiple studies have shown aerobic activity is better than other types of exercise when it comes to reducing the result of a heart attack. Here's what you should know... Aerobic activity – also known as cardio, referencing the Greek word for the heart – exercises the cardiovascular and respiratory systems, getting the heart to beat faster, according to Mayo Clinic. Over time, regular cardio can mean can mean your heart doesn't have to work as hard, Cleveland Clinic notes. Aerobic exercise can strengthen the blood vessels, improve the flow of oxygen throughout the body, lower blood pressure, increase 'good' cholesterol, and help to reduce the risk of heart disease – including coronary heart disease – and stroke. High blood pressure can lead to heart attack. Anaerobic exercise, including strength and high intensity interval training, can also strengthen the heart and lungs. But, the benefits are different. 'Aerobic exercise and resistance training are the most important for heart health,' Johns Hopkins exercise physiologist Kerry Stewart said. 'Although flexibility doesn't contribute directly to heart health, it's nevertheless important because it provides a good foundation for performing aerobic and strength exercises more effectively.' Well, federal health authorities say American adults need at least 150 minutes of moderate intensity physical activity each week. That's also what Laffin recommends, although the benefits grow if you do oven more. The Baylor College of Medicine says splitting the 150 minutes into 30-minute intervals allow for five active days and two rest days. 'Jog, swim, golf, hike, play basketball, dance, do yoga — whatever you love to do. The most important thing is to get out there and do it,' UT Southwestern Medical Center cardiologist Dr. Ben Levin advises.
Washington Post
28 minutes ago
- Washington Post
New CDC advisers will skip some expected topics and explore a target of antivaccine activists
U.S. Health Secretary Robert F. Kennedy Jr.'s new vaccine advisers meet next week, but their agenda suggests they'll skip some expected topics — including a vote on COVID-19 shots — while taking up a longtime target of anti-vaccine groups. The Advisory Committee on Immunization Practices makes recommendations on how to use the nation's vaccines, setting a schedule for children's vaccines as well as advice for adult shots. Last week, Kennedy abruptly dismissed the existing 17-member expert panel and handpicked eight replacements , including several anti-vaccine voices. The agenda for the new committee's first meeting, posted Wednesday, shows it will be shorter than expected. Discussion of COVID-19 shots will open the session, but the agenda lists no vote on that. Instead, the committee will vote on fall flu vaccinations, on RSV vaccinations for pregnant women and children and on the use of a preservative named thimerosal that's in a subset of flu shots. It's not clear who wrote the agenda. No committee chairperson has been named and the U.S. Department of Health and Human Services did not comment. Missing from the agenda are some heavily researched vaccine policy proposals the advisers were supposed to consider this month, including shots against HPV and meningococcal bacteria, said Dr. Susan Kressly, president of the American Academy of Pediatrics. Instead, the committee is talking about subjects 'which are settled science,' she said. 'Every American should be asking themselves how and why did we get here, where leaders are promoting their own agenda instead of protecting our people and our communities,' she said. She worried it's 'part of a purposeful agenda to insert dangerous and harmful and unnecessary fear regarding vaccines into the process.' The committee makes recommendations on how vaccines that have been approved by the Food and Drug Administration should be used. The recommendations traditionally go to the Centers for Disease Control and Prevention director. Historically, nearly all are accepted and then used by insurance companies in deciding what vaccines to cover. But the CDC has no director and the committee's recommendations have been going to Kennedy. Thimerosal was added to certain vaccines in the early 20th century to make them safer and more accessible by preventing bacterial contamination in multi-dose vials. It's a tiny amount, but because it's a form of mercury, it began raising questions in the 1990s. Kennedy — a leading voice in an antivaccine movement before he became President Donald Trump's health secretary — has long held there was a tie between thimerosal and autism, and also accused the government of hiding the danger. Study after study has found no evidence that thimerosal causes autism. But since 2001, all vaccines manufactured for the U.S. market and routinely recommended for children 6 years or younger have contained no thimerosal or only trace amounts, with the exception of inactivated influenza vaccine. Thimerosal now only appears in multidose flu shot vials, not the single-shot packaging of most of today's flu shots. Targeting thimerosal would likely force manufacturers to switch to single-dose vials, which would make the shots 'more expensive, less available and more feared,' said Paul Offit, a vaccine expert at Children's Hospital of Philadelphia. Last week, 30 organizations called on insurers to continue paying for COVID-19 vaccines for pregnant women after Kennedy said the shots would no longer be routinely recommended for that group. Doctors' groups also opposed Kennedy's changes to the vaccine committee. The new members he picked include a scientist who researched mRNA vaccine technology and became a conservative darling for his criticisms of COVID-19 vaccines, a top critic of pandemic-era lockdowns and a leader of a group that has been widely considered to be a source of vaccine misinformation. The American Academy of Pediatrics has long put out its own immunization recommendations. In recent decades it has matched what the government recommended. But asked if they might soon diverge, depending on potential changes in the government's vaccination recommendations, Kressly said; 'Nothing's off the table.' 'We will do whatever is necessary to make sure that every child in every community gets the vaccines that they deserve to stay healthy and safe,' she said. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
29 minutes ago
- Yahoo
AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant
AbbVie recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in migraine treatment. Over the last month, AbbVie's stock price remained relatively flat, mirroring broader market trends. While the positive study results for Atogepant might have added slight upward pressure, this was tempered by overall market volatility influenced by geopolitical tensions and interest rate speculations. Additionally, other developments, such as the promising FDA label expansion for MAVYRET, might have reinforced investor confidence, but these factors were balanced by an overall stable market performance during the period. AbbVie has 5 possible red flags we think you should know about. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. The recent positive results from the Phase 3 TEMPLE study on Atogepant indicate potential revenue growth for AbbVie, as the company advances its pipeline in migraine treatment. This aligns with the company's strategic focus on expanding into areas like obesity and oncology. These therapeutic expansions, alongside promising developments like the FDA label expansion for MAVYRET, are designed to strengthen future earnings. While the stock price remained relatively flat in the short term, largely due to market volatility, these advances could positively influence future revenue and earnings forecasts. Over the past five years, AbbVie's total shareholder return, including dividends, reached 133.93%, demonstrating substantial long-term value for investors. Despite this strong growth, AbbVie's recent one-year performance underperformed the US market's return of 9.8%. Within the biotech sector specifically, AbbVie surpassed the industry average, which experienced a decline of 9.8% over the same period. Given AbbVie's current share price of US$187.15 and the consensus analyst price target of US$210.68, the stock appears to reflect potential upside. However, considering the revenue and margin pressures from biosimilar competition, particularly with key drugs like Humira facing competition, these forecast improvements are crucial. Investors should weigh these elements against the expected revenue growth rate and projected earnings of US$19 billion by 2028. Unlock comprehensive insights into our analysis of AbbVie stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABBV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
